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Abstract 
This review surveys some of the recent literature concerning the use of polymer coatings for a variety of 
biomedical applications. These have been grouped into six broad categories: orthopaedic materials, 
cardiovascular stents, antibacterial surfaces, drug delivery, tissue engineering and biosensors. These, to some 
extent overlapping, sections have been ordered such that the literature generally progresses from polymer 
coatings on metallic to non-metallic substrates. Polymer coatings can bestow a wide-range of functionalities due 
to their various properties, such as anti-wear and characteristics, mechanical strength, corrosion protection, 
electrical conductivity, biocompatibility and surface chemistry. The review period is from 2011 to the present 
(2013). 
Keywords: polymer coatings, conducting polymers, orthopaedics, cardiovascular stents, antibacterial surfaces, 
drug delivery, tissue engineering, biosensors 
List of abbreviations 
Cat-PAsp-PPhe  catechol-poly(L-aspartic acid)-b-poly(L-phenylalanine) 
hexylPVP  poly(vinyl-N-hexylpyridinium salts) 
L-PPE:O low-pressure plasma-polymerised ethylene film coatings rich in bonded oxygen 
groups 
PAn   poly(aniline) 
PAPBAOT  poly(3-aminophenyl boronic acid-co-3-octylthiophene) 
PCL   poly(-caprolactone) 
PDLA   poly(D-lactic acid) 
PDLLA   poly(D,L-lactide) 
PDMS   poly(dimethylsiloxane) 
PEDOT    poly(3,4-ethylenedioxythiophene) 
PEG   poly(ethylene glycol) 
PEGDA   poly(ethylene glycol diacrylate)  
PEI   poly(ethyleneimine) 
PET   poly(ethylene terephthalate) 
PGA   poly(glycolic acid) 
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PHA   poly(3-hydroxyalkanoate) 
PHBV   poly(hydroxybutyrate) / poly(hydroxyvalerate) 
PHBHV   poly(3-hydroxybutyrate-co-3-hydroxyvalerate) 
P(HBHV-b-LA)  poly((3-hydroxybutyrate-co-3-hydroxyvalerate)-b-(lactic acid)) 
PHO   poly(3-hydroxyoctanoate) 
PLA   poly(lactic acid) 
PLGA   poly(DL-lactic-co-glycolic acid) 
PLLA   poly(L-lactide) 
PMAA   poly(methacrylic acid) 
PMMA   poly(methyl methacrylate) 
POSS-PCL  polyhedral oliogmeric silsequioxane poly(-caprolactone) 
POSS-PCU  polyhedral oliogmeric silsequioxane poly(carbonate-urea) urethane  
PPy   poly(pyrrole) 
PSMA   poly(styrene)-co-poly(acrylic acid) 
PTFE   poly(tetrafluoroethylene) 
PVA   poly(vinyl alcohol) 
polyNaSS  poly(sodium styrene sulfonate) 
PU   poly(urethane) 
SIBS   poly(styrene-block-isobutylene-block-styrene) 
UHMWPE  ultra-high molecular weight poly(ethylene) 
 
 
Introduction 
Polymer coatings continue to be used in evermore increasingly diverse applications and sectors. From simple 
barrier coatings to elaborate nanotechnology-based composites, polymers offer a bastion of functionalities for 
their underlying hosts. In the field of biomedicine, such characteristics include wear-resistance, improved 
mechanical strength, corrosion protection, enhanced biocompatibility, electrical conductivity and tailored 
surface chemistry; switchable smart materials are even possible in at least the latter two cases. This paper 
reviews some of the recent literature, from 2011 to 2013, describing the use of polymer coatings for biomedical 
applications. The cited publications have been arranged into six main themes that seem to dominate; these 
include orthopaedic materials,
1-18
 cardiovascular stents,
19-40
 antibacterial surfaces,
41-54
 drug delivery,
55-70
 tissue 
engineering
71-83
 and biosensors.
84-101
 There is considerable crossover between these areas and certainly this 
review, as with others published in Transactions,
102-104
 is by no means exhaustive; rather, it represents an 
overview to whet the appetite, particularly for those readers considering how their existing skills and 
technologies could be extended into new sectors. With this in mind, the sections have been arranged to broadly 
span from polymer coatings on metallic to non-metallic surfaces. 
  
POST-PRINT VERSION: Trans IMF, 92(1) (2014) 9-19. DOI: 10.1179/0020296713Z.000000000157 
ISSN 0020-2967 (paper), ISSN 1745-9192 (online) 
 
3 
 
Applications 
Orthopaedic materials 
There has been much recent media attention on the ban of UK hospitals to perform metal-to-metal hip 
resurfacing due to corrosion and high levels of wear debris (metallosis).
105
 The use of ceramics or 
poly(ethylene) for the acetabular cup, which may also involve total hip placement (THR), usually offers an 
effective solution. Research into novel metallic and non-metallic coatings for orthopaedic materials, for a 
variety of applications, continues to be an area of interest. Magnesium and its alloys are attractive materials for 
potential temporary implantable devices due to their low density, great fracture toughness, and matched elastic 
modulii and compressive yield strengths relative to bone.
1,2
 The corrosion products are also non-toxic, although 
of course, a reduction in the corrosion rate of pure Mg is required. Luo et al. electropolymerised Mg with the 
conducting polymer poly(3,4-ethylenedioxythiophene) (PEDOT) from an ionic liquid electrolyte.
2
 The coating 
was found to reduce the corrosion rate and an anti-inflammatory drug, dexamethasone, incorporated into the 
electrolyte during electropolymerisation, was released upon subsequent electrical stimulation. 
Xu and Yamamoto reported that uniform, nonporous amorphous poly(L-lactide) (PLLA) coatings had better 
adhesion strength to Mg compared with semi-crystalline poly(-caprolactone) (PCL) layers – polymers 
investigated to reduce the corrosion rate of Mg and increase its cytocompatibility.
3
 Both polymers enabled good 
cell (SaOS-2) attachment and growth. Abdal-hay et al. investigated the effect of a spray-coating of 
hydroxyapatite (HA)-doped poly(lactic acid) (PLA) on the corrosion behaviour and bioactivity of AZ31 Mg 
alloy.
4
 Lower corrosion rates were reported following a 15-day in vitro test and cytocompatibility studies 
revealed increased cell growth. Kunjukunju et al. reported the fabrication of multi-layered coatings of alginate 
and poly(L-lysine), using a layer-by-layer (LbL) technique, on alkaline and F
-
 pre-treated AZ31 Mg alloys for 
the controlled delivery of growth factors and other biomolecules.
5
 The materials were further functionalised 
with FN to improve cell bioactivity, which was found to be the case. Electrospinning and dip-coating techniques 
were used by Abdal-hay et al. to coat PLA onto Mg alloy AM50; Ca-P and/or Ca-P-Mg layers lowered the 
corrosion rate and the surfaces promoted cell attachment (Fig. 1).
6
 Ivanou et al. found that sealing the anodic 
layers on ZE41 Mg alloy with an epoxy-silane coating markedly improved the corrosion resistance of the alloy 
in 0.6 M NaCl.
7
 
 
 
Figure 1. Schematic diagram illustrating the degradation mechanism and formation of a Ca/P layer on treated 
Mg alloy (AM50) surfaces upon immersion in simulation body fluid; porous coated film (left) and membrane 
coated film (right). Adapted from [6] and used with permission. 
 
 
Titanium and its alloys are commonly used as orthopaedic implants; however, bacterial infection and poor 
osseointegration have been identified as the main reason for orthopaedic implant failures. Gulati et al. produced 
a Ti implant with drug-eluting properties to locally deliver drug molecules to address these undesirable 
characteristics (Fig. 2).
8
 Ti surfaces were modified with titania nanotube (TNT) arrays that have incorporate the 
drug indomethacin with two biodegradable and antibacterial polymers, chitosan and PLGA. Drug delivery to the 
bone was demonstrated over an extended period, with liable kinetics and good biocompatibility. Incorporation 
and release of antibiotics in combination with growth factors is important for the prevention of infections and to 
stimulate bone healing. With this in mind, Strobel et al. incorporated three drugs (gentamicin for burst release, 
insulin-like growth factor I (IGF-I) for a burst release followed by a sustained release, and bone morphogenetic 
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protein-2 (BMP-2), to promote osteogenesis, for slow sustained release) into a poly(D,L-lactide) (PDLLA) 
coating on Ti.
9
 Sequential release of the three drugs was successfully demonstrated. Son et al. used 
biodegradable nanoparticle carriers for the release of drug molecules from Ti surfaces.
10
 Resorbable blast media 
(RBM)-treated Ti surface was prepared by blasting Ti with resorbable HA particles. Human serum albumin 
(HSA) nanoparticles loaded with vancomycin, pre-coated with positively charged poly(ethyleneimine) (PEI) 
molecules and then immobilised via electrical interaction on the Ti disc surfaces. Lee et al. also functionalised a 
Ti surface to release BMP-2 using Ti-adhesive nanoparticles self-assembled with catechol-poly(L-aspartic acid)-
b-poly(L-phenylalanine) (Cat-PAsp-PPhe) (Fig. 3).
11
 Controlled release of BMP-2 for 40 days and increased 
cell attachment were observed. 
 
 
 
 
Figure 2. Scheme of titania nanotube (TNT/Ti) implants modified with polymer film: (a) bare TNT layer formed 
on Ti substrate by electrochemical anodisation; (b) loading of drug inside TNT structures; (c) chitosan or PLGA 
polymer film coated on TNT by dip coating (thin and thick) with the aim of controlling drug release and 
improving antibacterial properties and bone integration. The scheme shows diffusion of drug molecules through 
the polymer matrix. Adapted from [8] and used with permission. 
 
 
Chebbi & Stokes produced flame-sprayed, biocompatible, biogradable (poly(hydroxybutyrate) / 
poly(hydroxyvalerate) (PHBV) 98:2) and non-biodegradable (poly(methyl methacrylate) (PMMA)) as single 
coatings on Ti and as top coatings on plasma sprayed HA.
12
 Spraying parameters were investigated using a 
Design of Experiments approach and good cell proliferation was reported. Oughlis et al. found that a polymer of 
sodium styrene sulfonate (polyNaSS) could be used as a scaffold on Ti to increase cell (human mesenchymal 
stem cells, hMSCs) spreading and differentiation;
13
 polyNaSS therefore has potential in bone tissue engineering. 
Hieda et al. examined differences in adhesion between a biomedical β-type Ti alloy, Ti-29Nb-13Ta-4.6Zr 
(TNTZ), and poly(urethane) (PU), caused by the addition of different silane layers.
14
 A ten-fold increase in 
shear bonding strength was found, with 3-methacryloxypropyltrimethoxysilane (-MPTS) being particularly 
notable for its water resistance when exposed for 30 days. 
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Figure 3. Schematic illustration showing formation of Ti-adhesive nanoparticles, immobilisation on Ti 
substrates and subsequent loading and release of BMP-2. Adapted from [11] and used with permission. 
 
 
Atomic force microscopy (AFM) and field emission scanning electron microscopy (FE-SEM) was used by Liao 
et al. to assess the morphology of Ti coated with nanostructured poly(pyrrole) (PPy) – a conducting 
polymer.
106,107
 The roughness of the deposit, for improved osteoblast adhesion, could be controlled by varying 
the duration of the electropolymerisation reaction. Mindroiu et al. electrodeposited PPy on Ti6Al7Nb using 
different electrolytes with the aim of producing materials of improved biocompatibility and antimicrobial 
activity.
16
 Synthesis conditions were found to be correlated with biological properties. Using a dip-coating 
method, a thin film of ultra-high molecular weight poly(ethylene) (UHMWPE) was applied to Ti6Al4V by 
Panjwani et al.
17
 High wear durability and adequate cytotoxicity test results (ISO 10993-5) were achieved. 
Further improved wear performance was found using an overcoat of perfluoropolyether (PFPE). 
Madhan Kumar & Rajendran coated 316-stainless steel with a PPy/TiO2 nanocomposite using cyclic 
voltammetry.
18
 Biocompatibility tests in simulated body fluid (SBF) proved successful and the corrosion rate of 
the underlying substrate was reduced. 
 
Cardiovascular stents 
Bare-metal stents (BMS), introduced in 1994 for the treatment of coronary artery disease (CAD), have suffered 
problems associated with stent thrombosis and restenosis – recurrence of the vessel narrowing (stenosis).19 
First generation drug eluting stents (DES; DES-1) used sirolimus and paclitaxel (PTX) (immunosuppressants) 
on stainless steel, which generally reduced restenosis.
20,21
 However, some of these led to other clinical issues, 
such as late stage thrombosis, thought to be caused by cracking, flaking and delamination.
22
 Strut dimensions, 
geometry and positioning relative to vessel walls also play a key role in thrombogenicity.
23
 
Second generation DES (DES-2) used everolimus and zotarolimus on CoCr to lower rates of thrombosis.
19
 
Permanent polymer DES, such as the everolimus-eluting stent (EES) and sirolimus-eluting stent (SES), continue 
to be used and developed.
22
 Byrne et al. compared the clinical outcomes of EES and SES after three years and 
found them to be similar.
21
 Youssefian and Rahbar used simulation studies and AFM force measurements to 
investigate the poor adhesion between stainless steel 316 and parylene C (a chemical vapour-deposited, chlorine 
substituted poly(p-xylylene)) with and without a silane adhesion layer.
24
 The AFM results correlated well with 
the modelling studies, although silanisation did not improve adhesion characteristics. The biocompatibility of 
poly(styrene-block-isobutylene-block-styrene) (SIBS), the most common DES coating used in China, on Co-Cr 
was improved by Zhu et al. by increasing the sulfonic acid content.
25
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More recent strategies have been to produce carrier-free systems,
26
 such as rapamycin (RM) crystals grown 
directly on a CoCr stent,
22
 or biodegradable (bioabsorbable) DES on CoCr or Ni-Ti.
19
 The latter approach allows 
for slow degradation of the coating to inactive and soluble forms without causing the problems associated with 
the early durable polymers.
21,22
 For example, PLA, PDLLA and poly(DL-lactic-co-glycolic acid) (PLGA) 
undergo ester hydrolysis to yield lactic and glycolic acids that can be cleared without causing inflammatory 
responses.
27
 Moore et al. used a PLA-poly(ethylene glycol) (PEG) biocompatible block-co-polymer to coat 
carbon nanotubes (CNTs) to reduce their short-term and long-term toxicity and prevent their aggregation; the 
polymer also aided sustained drug release of PTX and reduced in vitro inflammation.
28
 
Bege et al. studied a reproducible, spray-coating process for stainless steel stents costing with the biocompatible 
and thermoelastic polymer poly(ethylene carbonate) containing PTX (Fig. 4).
20
 Abluminal (outer) surfaces were 
more thickly coated than luminal (inner) ones and diffusion-controlled release occurred within two months. The 
polymer coatings were investigated as biodegradable DES by Bian et al. and were compared to those produced 
using PLGA.
29
 The stability and release profiles (PTX and sirolimus) were found to be superior to the PLGA 
coatings. Karagkiozaki and co-workers found PEDOT coatings were cytocompatible and promoted human 
serum albumin adsorption and cell adhesion.
30
 
 
 
 
Figure 4. Homogeneity of the polymer film on stents. CLSM images of spray-coated PEC stents with 
incorporated coumarin-6 as fluorescent maker (10). Z-stack images of the coated stents were performed; (a and 
b) abluminal (outside) and (c and d) luminal (inside) stent side. Green: Coumarin-6 in the PEC layer. Adapted 
from [20] and used with permission. 
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Variation in solvent and spray parameters upon DES surface morphologies was investigated by Shanshan et al.
31
 
PLGA coating thickness, on stainless steel, could be controlled by flow rate, roughness by nozzle power, and 
polymer distribution on internal and external surfaces by rotation speed. The addition of PEG was also found to 
increase drug (sirolimus) release rates. Jian et al. produced an aspirin/stainless steel 316L DES with a 
silica/PEG matrix to aid flexibility.
32
 L-3,4-dihydroxyphenylalanine was used as a bio-adhesive and the drug 
was slowly released from the coating. Sirolimus release from stainless steel BMS stents sprayed with degradable 
poly(3-hydroxyalkanoate)s (PHAs), i.e., natural poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBHV), 
poly(3-hydroxyoctanoate) (PHO), functional polyesters containing carboxylic groups and the diblock copolymer 
poly((3-hydroxybutyrate-co-3-hydroxyvalerate)-b-(lactic acid)) P(HBHV-b-LA), were investigated by Vergnol 
et al.
33
 The bilayer systems offered many options for controlled release, including a burst effect. 
Anti-vascular endothelial-cadherin (VE-cadherin) antibodies were attached to silanised and PEG-grafted 
stainless steel using a dip-coating by Kang and co-workers.
34
 These antibodies are specifically expressed on the 
surfaces of endothelial progenitor cells (EPCs) and are important in cell proliferation and signalling. Non-
specific biofouling was reduced and re-endothelialisation was achieved within three days.  Shen et al. sprayed a 
heparin-immobilised copolymer of L-lactide (LA) and 5-methyl-benzyloxycarbonate-1,3-dioxan-2-one (MBC) 
(9:1) in tetrahydrofuran (THF) on to BMS.
35
 The films were fully degraded in 16 weeks in vitro and in vivo, 
with only mild inflammation being exhibited. 
Tan et al. speculates on a new generation of stents that use nanocomposite biodegradable polymers, such as 
polyhedral oliogmeric silsequioxane poly(carbonate-urea) urethane (POSS-PCU) and POSS PCL, with 
endothelial progenitor cell (EPC)-specific antibodies to promote cell growth and nitric oxide (NO)-eluting 
polymers for thrombosis prevention and maintaining healthy endothelial surfaces (Fig. 5).
36,37
 LbL coating 
technologies could also be used for multiple drug delivery. In a letter to the Lancet, Waksman & Maluenda 
concluded that although biodegradable polymer technology is appealing, it still remains to be confirmed whether 
this strategy will replace durable polymers for DES.
38
 The field has been recently reviewed in depth.
19,39,40
 
 
 
 
Figure 5. A three-pronged approach for the next generation of coronary stents: (i) nanocomposite polymer 
coatings, such as POSS-PCU with EPC-specific antibody attachment for enhanced endothelialisation; (ii) NO-
eluting polymers for thrombosis prevention and promoting healthy endothelial surfaces; and (iii) LbL coatings 
(e.g., POSS-PCU and POSS-PCL) for multiple drug release [36,37]. Used with permission. 
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Antimicrobial surfaces 
Antimicrobial surfaces, prepared by chemical and physical approaches, have been recently reviewed by Hasan 
et al.
41
 With regard to polymer coatings, the review makes the distinction between structural polymers grafted 
with antibacterial polymers, e.g., poly(vinyl-N-hexylpyridinium salts) (hexyl PVP), and those incorporating 
(entrapping) antimicrobial compounds, e.g., antibiotics, Ag
+
 and F
-
. Substrates generally appear to be metallic 
implants, although other materials have been coated. Interestingly, the authors note that greater importance 
needs to be paid to surface topography (nanotopography) for the fabrication of new generation antimicrobial 
biomaterials. 
Simple antimicrobial PU coatings, reported by Bakhshi et al., were prepared by coupling quaternary ammonium 
salts bearing reactive hydroxyl groups on to the backbone of soyabean oil, conversion to polyols and 
subsequently reacting with diisocyanate monomers.
42
 The coatings showed good mechanical properties and 
adhesion strength and were found to reduce bacterial activity by up to 95%, suggesting their promise as implant 
coating materials. 
Cristescu et al. used matrix assisted pulsed laser evaporation (MAPLE) to deposit thin films of poly(1,3-bis-(p-
carboxyphenoxy propane)-co-sebacic anhydride) 20:80 containing gentamycin on Si(100) and quartz 
substrates.
43
 Controlled drug delivery was demonstrated and films were shown to be effective against E. coli and 
S. aureus populations, suggesting their potential for use with catheters and implants. 
Electrosynthesised hydrogels on to Ti surfaces from aqueous solutions containing 2-hydroxyethyl methacrylate 
(HEMA), poly(ethylene glycol diacrylate) (PEGDA) and acrylic acid (AA) were reported by Di Giglio et al.
44
 
Polymers were loaded with ciprofloxacin (CIP), either during or after the polymerisation step, and in vitro 
inhibition against methicillin-resistant S. aureus (MRSA) was evaluated. The same drug was incorporated into a 
deposited low-pressure plasma-polymerised ethylene film coatings rich in bonded oxygen groups (L-PPE:O) on 
poly(ethylene terephthalate) (PET) by Jose Garcia-Fernandez et al.
45
 Sustained release of CIP was monitored 
over several hours and inhibition of S. aureus was observed, suggesting the coating would be attractive for 
medical devices. 
The use and fabrication of polymer coatings for controlled release of the new generation, broad-spectrum 
biocide, nanosilver, has been reviewed by Guo et al. and Knetsch & Koole.
46,47
 Composite polymer coatings 
were found to offer improved biocompatibility. Pishbin et al. used the natural polysaccharide, chitosan, together 
with Bioglass® particles (9.8 µm) and Ag nanoparticles (AgNP) to produce a composite orthopaedic coating 
following a one-step electrophoretic deposition process.
48
 Release of Ag
+
 (< 2.5 ppm) was effective against S. 
aureus for up to 10 days. Osteoblast cell proliferation was supported, but maintaining an AgNP content below 
342 µg was important to ensure no cytotoxic effects. Liu et al. investigated AgNP/PLGA-coated stainless steel 
alloy (SNPSA) for potential use as an antimicrobial implant material.
49
 The material was found to reduce 
microbial populations and also promoted osteoblast proliferation. 
Gao et al. grafted hydrophilic poly(acrylamide) brushes coupled to a series of antimicrobial peptides (AMPs) to 
produce infection-resistant implant coatings.
50
 Biofilm resistance, in vitro and in vivo, was demonstrated and 
toxicity to osteoblasts and platelet adhesion were not observed. Williams and co-workers incorporated into 
poly(dimethylsiloxane) (PDMS) a novel antimicrobial agent cationic steroid antimicrobial-13 (CSA13), a 
convenient synthetic analogue to naturally occurring AMPs.
51
 The coating system was tested against MRSA 
with an in vitro flow-through cell design. 
To minimise the risk of post-implantation infection, Guillaume et al. coated poly(propylene) meshes with dual 
drug-release degradable polymers (PCL/PLA) containing ofloxacin and rifampicin (Fig. 6).
52
 Sustained release 
of the antibiotics for 72 h was observed and surfaces were more rapidly invaded by fibroblasts than the uncoated 
substrate. 
Ding et al. coated silicone rubber, a commonly used a catheter material, with a range of PEG/cationic 
poly(carbonate) block copolymers via a poly(dopamine) coating with the aim of reducing intravascular catheter 
infections (CAIs).
53
 Polymers with a more hydrophobic component were found to kill methicillin-susceptible S. 
aureus (MSSA) and MRSA; blood protein adsorption and platelet adhesion was not observed. 
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Figure 6. Drug release profiles from ofloxacin + rifampicin-coated meshes prepared using different coating 
strategies: (a) bilayer coating based on a first coating consisting of ofloxacin (1 mg) and rifampicin (1 mg) 
dispersed in PCL (10 mg) and a second coating consisting of PCL (10 mg; per 9 cm
2
 mesh) followed by rapid 
heating; (b) tri-layer coating based on a first coating consisting of ofloxacin (1 mg) dispersed in PCL (5 mg), a 
second coating consisting of rifampicin (1 mg) dispersed in PCL (5 mg), and a third coating consisting of PCL–
PLA (10 mg; per 9 cm
2
 mesh) followed by rapid heating. Adapted from [52] and used with permission. 
 
Antimicrobial polymer coatings were also prepared by Han et al. by dip-coating glass slides into a solution of 
dodecyl quaternary ammonium, methoxyethyl and catechol groups with subsequently drying and heating.
54
 The 
functional groups respectively allowed biocide, hydrophilic/hydrophrobic balance and immobilisation to take 
place. Surfaces were resistant to E. coli, S. aureus and Acinetobacter baumannii for up to 96 h. 
 
Drug delivery 
Drug delivery systems display diverse pharmacokinetic profiles with variations in size, shape, chemical 
composition and surface characteristics, and are classified according to whether they are purely organic, 
organic-inorganic or purely inorganic. The main goals in drug delivery are to improve the drugs’ bioavailability, 
decrease their therapeutic dose to reduce possible side effects and so increase safety, to enable targeted drug 
delivery and to approach personalised medicine for the long term future.
55
 Therefore, new formulations are 
being studied to achieve a greater pharmacological response, and to deliver and control the release of drug 
molecules; these are being tested with several types of polymers with a variety of physicochemical properties. 
However, synthetic polymers may cause toxicity problems due to their degradation in vivo, and natural polymers 
usually face reproducibility problems due to the difficulty in controlling monomer purity. Polymeric matrices, 
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both synthetic and natural, have been used continuously as drug delivery vehicles. Natural polymers, such as 
dextrans, chitosan, sodium alginate, lignin and cellulose derivatives, are particularly interesting due to their 
higher biodegradability and biocompatibility compared with many synthetic polymers.
56
 Goh et al., in a review 
paper in 2012, emphasised the role of alginates in microencapsulation and therapeutic applications.
57
 These 
materials provide good drug delivery matrices, where the release could be controlled by changing various 
factors such as cation type, porosity and composition of alginate, pH and drug molecular mass. Moreover, the 
good mechanical properties of alginates make them a valuable product for the treatment of wound healing and 
tissue repair. 
Microneedles are being increasingly used in drug delivery.
58
 These have the potential to overcome many of the 
disadvantages associated with traditional hypodermic needle. In addition, coated microneedle patches have 
demonstrated potential for effective, minimally invasive, drug and vaccine delivery. Processing parameters such 
as concentration of coating material, liquid input rate, duration of spraying, atomisation air pressure, gun-to-
surface distance and air cap setting are very important.
59
 McGrath et al. spray-coated microneedle patches using 
a conventional film coating process, and investigated two film-coating materials, hydroxypropylmethylcellulose 
(HPMC) and carboxymethylcellulose (CMC); these could be potentially drug loaded for intradermal drug and 
vaccine delivery.
59
 
In addition to cardiovascular applications described above, stents have been used for treating other diseases. 
Moon et al., for example, deposited a layer of acetylated polysaccharides on a poly(tetrafluoroethylene) (PTFE) 
coated self-expandable non-vascular metallic stent (EMS).
60
 Gemcitabine, for astrointestinal cancer and cancer-
related stenosis, was incorporated in the acetylated layer and sustained release was observed over 30 days; 
tumour regression was also noted. 
Craig et al. tethered the active component of cis-platin, cis-{Pt(NH3)}
2+
, to gold nanoparticles (AuNP) via PEG 
linkers to produce drug delivery vehicles for this anticancer agent.
61
 Improved formulation reproducibility, drug 
loading, stability and cytotoxicity were achieved. 
Aznar-Cervantes et al. coated electrospun silk fibroin meshes with chemically polymerised PPy.
62
 Chemical 
attachment was confirmed and the meshes offered improved mechanical resistance; drug (anion) storage and 
delivery could be controlled electrochemically. Antischistosomiasis drugs (praziquantel and trichlorfon) were 
also incorporated into PPy coatings on Pt, indium-tin oxide glass and reticulated vitreous carbon (RVC) by Li et 
al.
63
 Electrochemical release of trichlorfon was demonstrated. Tsai and co-workers incorporated indomethacine, 
used to alleviate chronic pain, into PVA on conductive poly(aniline) PAn;
64
 controlled, electro-stimulated 
release of the drug reduced problems associated with gastric irritation. 
Tang et al. investigated effect of pH on drug delivery by using a pH-responsive polymer shell (chitosan / 
poly(methacrylic acid) (CS-PMAA)) for coating mesoporous silica nanoparticles (MSN), and then combined 
them with the drug molecule doxorubicin hydrochloride (DOX) to investigate drug storage and release 
behaviour.
65
 The results demonstrated that DOX could be effectively loaded into the composite microspheres. 
Tarafder et al. examined lovastatin release behaviour from a PCL coating on β-tricalcium phosphate (β-TCP) to 
investigate the effects of pH, concentration and drug–polymer interactions.66 They found that the hydrophilic–
hydrophobic and hydrophobic–hydrophobic interactions between lovastatin and PCL could be a key factor on 
controlling the diffusion dominated release kinetics over dissolution and degradation processes. 
Casting, printing, electrospinning and melt extrusion have been used increasingly for the preparation of implants 
(biodegradable and non-biodegradable) for the treatment of diseases such as cancer and epilepsy; these materials 
combine hydrophobic drug molecules with polymers for the successful release/targeting of drugs.
67
 Polymers 
may also be functionalised appropriately to aid the coupling of bio-inert layers on implants, which are 
biologically inactive. Phosphoryl choline, commonly used in contact lenses, is such an example. Laga et al. 
reviews the many uses of hydrophilic polymer coatings for medicinal applications, including those for gene 
delivery.
68
 
The field of polymer coatings for colon delivery have been reviewed by Maroni et al.
69
 These are mainly in the 
form of functional coatings applied to solid dosage forms that are protected from gastric and small intestinal 
fluid exposure. Release mechanisms are mainly based on pH changes, time-dependent break-up, microbial 
enzymatic activity.   
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The sensitivity of controlled release dosage forms to the presence of ethanol in the gastro intestinal tract is also 
critical, which is for instance the case for most opioid drugs. Therefore, Rosiaux et al. prepared controlled 
release film coatings that are ethanol-resistant, by using blends of ethyl cellulose with medium or high viscosity 
guar gums.
70
 The release of theophylline from pellets coated with the aqueous ethyl cellulose dispersion 
Aquacoat® ECD 30 was unaffected in the presence of ethanol (40%) in the release medium. 
Polymeric coatings have been also used on cochlear implants.
71
 Chikar et al. combined an arginine-glycine-
aspartic acid (RGD)-functionalised alginate hydrogel with a PEDOT conducting polymer to produce a non-
cytotoxic coating with low electrode impedance.
71
 The hydrogel was soaked in brain-derived neurotrophic 
factor (BDNF), important for auditory nerve survival and cochlea development and maintenance. 
 
Tissue engineering 
The fabrication of polymer coatings plays a critical role in tissue engineering applications, since 
biocompatibility and elasticity are important parameters in this field.
72
 Biomaterials used for tissue engineering 
applications include thermoplastic rubbers, physically (such as PUs, PHA-based polymers, PCL copolymers 
with glycolide or lactide) and chemically cross-linked elastomers (such as poly(polyol sebacate), poly(diol 
citrate), silicone elastomers), elastic proteins (such as collagen, elastin, fibrin, titin, resilin, gluten), and 
elastomer-based ceramic-filled composites.
72
 Natural polymers such as starch, gelatin, alginate, cellulose and 
chitin represent attractive candidates for tissue culture application.
73
 One disadvantage of natural polymers 
comparable to synthetic polymers is that are not bio-based. Croisier & Jérôme, however, prepared a bio-based 
polymer using chitosan for use in 3D-scaffolds as gels and sponges, and in 2D-scaffolds as films and fibres, 
which could be very attractive for tissue engineering.
73
 The use of chitosan-based polymers for use as cartilage 
scaffolds for such applications has been reviewed by Iwasaki et al.
74
 Lamprou and co-workers used gelatine and 
gelatine/elastin (different ratios) for the preparation of tubular nanocomposite gels and investigated them on rat 
smooth muscle cells (SMCs) for their use in tissue engineering of vascular grafts.
75
 They found that gels were 
stable with mechanical behaviour (microstructure and stiffness) similar to natural arteries. 
Tissue scaffolds that provide 3-D geometry and mechanical structure are mandatory for vascular tissue 
engineering applications, since most current synthetic scaffolds are not suitable. Dubey & Mequanint 
investigated fibronectin (FN) conjugation onto highly porous 3-D poly(carbonate) urethane scaffolds through 
grafted poly(acrylic acid) spacers on the urethane backbone.
76
 These showed improved cell attachment and 
infiltration depth compared with scaffolds without FN conjugation. Tsai et al. found proliferation of 
chondrocytes (cartilage cells) on poly(dopamine)-coated 3-D porous scaffolds of polymers such as PCL, PLGA, 
PU and biodegradable polymers.
77
    
The development of clinically relevant scaffold-based for bone tissue engineering (BTE) therapy is an important 
area that is of increasingly interest due to challenges relating to osseointegration of bioresorbable scaffolds and 
bone infection management.
78
 BTE scaffold materials comprise of ceramics, composites and biodegradable 
(synthetic and natural) polymers; some regulatory approved polymers include poly(glycolic acid) (PGA) and 
poly(lactide)s (such as PLLA and poly(D-lactic acid) (PDLA)).
78
 Synthetic degradable polymers, such as PLLA, 
PGA, PLGA, PCL, and PU, have also been approved for clinical use polymer scaffolds.
77
 The biodegradable 
synthetic polymers, such as PLLA, are often coated with collagen to prepare porous sponge surfaces for tissue 
engineering.
79
 Mathews et al. has investigated the effect of chitosan, collagen type 1 and hyaluronic acid on 
coating tissue culture plates for BTE application to evaluate their effect on osteogenic differentiation of human 
bone marrow derived mesenchymal stem cells (hMSCs).
80
 Modification improved osteoblast differentiation, 
mineralisation and osteoconductivity. 
Polymer coatings are also showing promise for neural prostheses, where the main challenge has been the 
development of highly stable and reliable microelectrode arrays (MEAs). For such applications, multiwall 
carbon nanotube (MWCNT)-doped PEDOT composite films have been electropolymerised onto Pt 
microelectrodes.
81
 Graphene has been also investigated for neural prostheses.
82
 
Ameringer et al. produced brush-type copolymers of PEG methyl ether methacrylates and poly((meth)acrylates) 
bearing spacer groups onto amine-functionalised poly(styrene) cell culture surfaces, followed by covalent 
immobilisation of cyclic peptides.
83
 The aim was to control biointerfacial interactions with HeLa cells whilst 
reducing non-specific interactions for improved biomedical devices; the effectiveness of the system was 
demonstrated. 
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Nandivada and co-workers developed the first polymer coating, poly[2-(methylacryloyloxy) ethyl dimethyl-(3-
sulfopropyl) ammonium hydroxide] (PMEDSAH) applied to poly(styrene) dishes, that sustains long-term 
growth of human embryonic stem (hES) cells in different culture media.
84
 
 
Biosensors 
Nambiar & Yeow reviewed the use of conducting polymers as sensors for clinical applications.
85
 The attraction 
of these materials is in their flexibility, biocompatibility and ease of deposition. An enzyme-free glucose sensor 
was produced by Ciftci et al. using the conducting polymer poly(3-aminophenyl boronic acid-co-3-
octylthiophene) (PAPBAOT) on a glassy carbon electrode (Fig. 7).
86
 The biosensor showed no response to 
ascorbic acid, dopamine or uric acid and a glucose detection limit of 0.5 mm was exhibited. Mazeiko et al. 
immobilised glucose oxidase (GOx; for the detection of glucose), with and without AuNPs, in a Pan layer on 
carbon rod electrodes.
87
 The catalytic properties of the enzyme were maintained in this novel nanocomposite 
that shows promise for amperometric biosensors as well as for other nanotechnological applications. 
 
 
 
 
Figure 7. (a) Chemical structures of octylthiophene (OT) and 3-aminophenylboronic acid (APBA); (b) possible 
structure of PAPBAOT copolymer; and (c) schematic illustration of the interaction of PAPBAOT with glucose. 
Adapted from [86] and used with permission. 
 
 
POST-PRINT VERSION: Trans IMF, 92(1) (2014) 9-19. DOI: 10.1179/0020296713Z.000000000157 
ISSN 0020-2967 (paper), ISSN 1745-9192 (online) 
 
13 
 
Kiilerich-Pedersen et al. produced an inexpensive, label-free, all-polymer electrochemical biosensor (conducting 
polymer PEDOT:OTs) for the detection of acute viral disease in human cell culture.
88
 Changes in impedance 
correlated with AFM and scanning ion conductance microscopy observations. A disposable enzyme biosensor 
was reported by Serafín et al., where the same polymer was deposited on AuNP-modified screen-printed carbon 
electrodes from an ionic liquid (1-butyl-3-methylimidazolium hexafluorophosphate) (BMIMPF6) containing 
alcohol dehydrogenase (ADH) or Tyrosinase.
89
 The use of this electrolyte offers great potential for 
incorporating enzymes into many of the conducting polymers hitherto only accessible via organic solvents. 
ElKaoutit et al. used a matrix of Nafion (perfluorosufonic acid polymer) and glutaraldehyde to entrap 
horseradish peroxidase onto PPy.
90
 The enzyme was incorporated in its native state and hence peroxide sensing 
was permitted in the absence of a mediator. A PPy and poly(thiophene) solid phase microextraction (SPME) 
fibre coatings for the rapid determination of the antibiotic amoxicillin in small volumes of human plasma was 
produced by Buszewski et al.
91
 
Osmium-modified redox polymers were incorporated as mediators into GOx electrodes by Conghaile and co-
workers.
92
 The complexes were coupled to epoxy-functionalised polymers of various compositions on graphite 
and they showed promise for use in glucose oxidising biosensors. Wang et al. used PLGA microspheres 
dispersed in a poly(vinyl alcohol) (PVA) hydrogel as a drug releasing layer for use with implantable GOx 
biosensors to reduce local inflammation.
93
 Feasibility of the study was demonstrated. PLGA was also used to 
produce nitric oxide reducing layer (for anti-platelet/anti-inflammation) for use with intravenous amperometric 
needle-type GOx/lactate electrodes.
94
 Release of NO for more than one week and a reduction in thrombus 
formation were observed. 
PU coatings have also been reported by a number of authors. Popescu et al. reported a method for producing 
HA-functionalised PU nanostructured films on Si/SiO2/Ti/Au.
95
 HA and PU, respectively, combine 
biocompatibility and mechanical properties and the hybrid offers promise for the construction of impedance 
biosensors for bone disease diagnosis and therapy. The effects of the electrospinning conditions of PU coatings 
on GOx biosensors have been investigated by Wang et al.
96
 Control of the fibro-porous structure and thickness 
of the electrospun coatings was found to have little effect on electrode sensitivity. 
Chang et al. used a biocompatible polymer poly(p-xylylene) (parylene) to coat CNTs grown on a poly(imide) 
substrate.
97
 The insulating coating permitted this flexible biosensor to be suitable for human serum albumin 
detection (3  10-11 mg/ml) in vivo. Stable glutamate dehydrogenase (GDH) biosensors crosslinked with PEI 
were produced by Garcia-Galan et al.
98
 Biotechnological uses for this enzyme have been unreported to date, 
owing to their poor stability. Varma described a method for fabricating thin-film, disposable reflectance 
biosensors based on polymers, e.g., poly(carbonate), that are orders of magnitude cheaper than their 
semiconductor counterparts.
99
 
Lv et al. reviewed the literature for the preparation of polymers imprinted with various proteins that exhibit 
antibody-like specificity.
100
 Various applications are presented, although these materials still present many 
challenges. A polymer coating for detection of specific monoclonal antibody 10B2 (MAb 10B2) against 
bacterium Acidovorax avenae subsp. citrulli (Aac) was reported by Puttharugsa et al.
101
 This was produced by 
immobilising a monolayer of Aac antigen on 95:5 poly(styrene)-co-poly(acrylic acid) (95PSMA). The polymer 
proved successful in antibody screening experiments. 
 
Concluding remarks 
Polymer coatings are extensively used for biomedical applications and continue to show great promise. They 
bestow a vast range of functionality to their underlying metallic and non-metallic hosts, such as improved wear-
resistance, mechanical strength, corrosion protection, biocompatibility, electrical conductivity and tailored 
surface chemistry. There are numerous application areas, with many of these being concentrated in the areas of 
orthopaedics, cardiovascular stents, antibacterial surfaces, drug delivery, tissue engineering and biosensors. 
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